HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 26, Nos. 09 & 10, September & October 2022 – Toxins and Medicines – Two Sides of the Same Coin       » Utilising Metal Nanoparticles as Plant Growth Regulators to Improve Crop Yield       » Remedy or Poison? How Microplastics Influence Copper Ion Toxicity in Aquatic Plants       » Synthesising Schiff Base Antimicrobial Copper Complexes With Unprecedented Speed       » Enhancing the Understanding of Past Infections With Machine Learning       » Mini, Cellular Bioweapons: Understanding the Structure and Mechanism of Stinging in Sea Anemone Nematocysts       » Converting Dead Spiders Into Gripping Tools
NEWS CRUNCH
Zika Virus Urgently Needs Improved Detection Methods as Vaccine Development Faces Array of Obstacles, says GlobalData Analyst
LONDON, UK (GlobalData), 16 February 2016 - The growing threat of the Zika virus, which the World Health Organization believes could infect four million people in the Americas over the next twelve months, must be addressed using a multi-pronged approach, according to an analyst with research and consulting firm GlobalData.

Mirco Junker, Ph.D., GlobalData's Analyst covering Infectious Diseases, says that while a vaccine could be an effective measure in the long term, it remains several years away and faces numerous obstacles to development. As such, limiting people's contact with mosquitoes and developing effective diagnostic tests are more crucial short-term measures.

Junker explains: "The first step in fighting the Zika virus is to address the vector responsible for its transferral to humans - mosquitoes. Achievable actions, such as eliminating shallow standing water, using insecticides, and implementing next-generation genetic or microbiological approaches, would all contribute to the reduction of Zika vector populations.

"Furthermore, the development of a reliable and cost-effective method to detect Zika infections is of paramount importance. The test would need to be sensitive and specific, with high cost-effectiveness, so that it may be employed on a large scale and be able to detect the large proportion of disease cases which are asymptomatic."

The analyst adds that while an effective long-term solution would be a vaccine that offers strong and durable protection against Zika, this could take years to become a reality.

Junker continues: "Several companies, including GlaxoSmithKline, Merck, Johnson & Johnson, Pfizer, and Sanofi, have already expressed interest in developing a Zika virus vaccine, but the current lack of scientific data on Zika presents a major barrier.

"The development of Sanofi's vaccine for dengue, a disease carried by the same type of mosquito as Zika, has taken 20 years, and its efficacy in certain patient populations, most notably flavivirus-na?ve individuals, has still not been definitively proven.

"Therefore, even though the Zika virus has been sequenced, it is currently not clear what the best approach in developing a Zika virus vaccine will be, and a definitive timeline on vaccine development is impossible to ascertain."

Source: GlobalData
FORTHCOMING ISSUE  
What Has Covid Ever Done for Us?
NEWS CRUNCH  
news 2022 PDA Aseptic Processing of Biopharmaceuticals Conference
news Thailand LAB INTERNATIONAL, Bio Asia Pacific, and FutureCHEM INTERNATIONAL are ready to offer the Science and Technology Industry complete solutions this September!
news Better together: registration opens for Vitafoods Asia 2022 co-located with Fi Asia in October
news 2022 PDA Pharmaceutical Manufacturing & Quality Conference
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   [email protected] or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   [email protected]
Copyright© 2022 World Scientific Publishing Co Pte Ltd  •  Privacy Policy